Structure Therapeutics Inc. GPCR, +73.33% priced 10.74 million American depositary shares at $15 each to raise $161 million in its initial public offering with joint book-running managers Jefferies, SVB Securities, Guggenheim Securities, and BMO Capital Markets. The IPO from the California-based biopharmaceutical company that’s developing oral therapeutics priced at the top end of its estimated price range of $13 to $15 a share. In a sign of healthy demand for its stock, Structure Therapeutics also increased the size of the offering to 10.74 million shares from 8.95 million shares. The company is developing GSBR-1290 as an oral small molecule product candidate for the treatment of type-2 diabetes mellitus, or T2DM, and obesity.
This article was originally published by Marketwatch.com. Read the original article here.
